|Mr. Ronald C. Renaud Jr.||CEO & Director||885.47k||488.19k||1969|
|Mr. Paul D. Burgess J.D.||Chief Legal Officer, COO & Sec.||596.55k||N/A||1974|
|Dr. Richard Wooster||Chief Scientific Officer||596.55k||N/A||1965|
|Dr. Ann Barbier M.D., Ph.D.||Chief Medical Officer||610.55k||N/A||1964|
|Dr. E. Rand Sutherland||Pres||N/A||N/A||N/A|
|Mr. Brendan Smith M.B.A.||CFO, Corp. Strategy & Principal Financial Officer||N/A||N/A||1976|
|Mr. Robert D. Prentiss||VP, Corp. Controller, Treasurer & Interim Principal Accounting Officer||N/A||N/A||1972|
|Mr. Frank DeRosa||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Teri Babine Dahlman||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Paula A. Cloghessy||Chief People Officer||N/A||N/A||1971|
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Translate Bio, Inc.’s ISS Governance QualityScore as of June 30, 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 8.